AR076147A1 - Fusiones y conjugados de farmaco. composicion farmaceutica. uso. procedimiento. - Google Patents

Fusiones y conjugados de farmaco. composicion farmaceutica. uso. procedimiento.

Info

Publication number
AR076147A1
AR076147A1 ARP100100946A ARP100100946A AR076147A1 AR 076147 A1 AR076147 A1 AR 076147A1 AR P100100946 A ARP100100946 A AR P100100946A AR P100100946 A ARP100100946 A AR P100100946A AR 076147 A1 AR076147 A1 AR 076147A1
Authority
AR
Argentina
Prior art keywords
dom
amino acid
dab
acid sequence
seq
Prior art date
Application number
ARP100100946A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42308293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR076147(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR076147A1 publication Critical patent/AR076147A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Reivindicacion 1: Una composicion de fusion o conjugado que comprende o está constituida por (a) un agente insulinotropico o un fármaco incretina presente como una fusion o un conjugado con, (b) un dAb que se une a albumina sérica seleccionado entre: (1) el anticuerpo de dominio (dAb) DOM 7h-14 (la secuencia de aminoácidos de DOM 7h-14 se muestra en la Figura 1 (h): SEC ID N°: 8), (ii) el anticuerpo de dominio (dAb) DOM 7h-14-10 (la secuencia de aminoácidos de DOM 7h-14-10 se muestra en la Figura 1 (o); SEC ID N°: 26) o un dAb que tiene hasta 4 diferencias de aminoácidos de la secuencia del dAb DOM 7h-14-10; y (iii) el dAb DOM 7h-11-15 (la secuencia de aminoácidos de DOM 7h-11-15 se muestra en la Figura 1 (p): SEC ID N°: 27) o (iv) el anticuerpo de dominio (dAb) DOM 7h-14-10 R108C (la secuencia de aminoácidos de DOM 7h-14-10 se muestra en la Figura 1(r). Reivindicacion 3: Una fusion o conjugado de acuerdo con la reivindicacion 1 o 2, en el que el fármaco se selecciona entre (a) el mutante A8G de GLP-1 (7-37) que tiene la secuencia de aminoácidos mostrada en la Figura 1 (i) (SEC ID N°: 9) o (b) la molécula de exendina-4 que tiene la secuencia de aminoácidos mostrada en la Figura 1 (j) (SEC ID N°: 10) o (c) PYY3-36 o PYY 3-36 que tiene una lisina en la posicion 10 y tiene la secuencia de aminoácidos mostrada en la Figura 1 s. Reivindicacion 13: Una composicion farmacéutica que comprende una fusion o conjugado de acuerdo con cualquiera de las reivindicaciones precedentes en combinacion con un vehículo, excipiente o diluyente farmacéutica o fisiologicamente aceptable. Reivindicacion 18: Uso de una composicion de acuerdo con una cualquiera de las reivindicaciones 1-15 en la preparacion de un medicamento para tratar o prevenir una enfermedad o trastorno metabolico. Reivindicacion 26: Un ácido nucleico aislado o recombinante que codifica una fusion de acuerdo con una cualquiera de las reivindicaciones 1 a 8, por ejemplo, una secuencia seleccionada entre: SEC ID N°: 50, 30, 29, 15-22. Reivindicacion 28: Un vector que comprende un ácido nucleico de las reivindicaciones 27 o 28. Reivindicacion 33: Una secuencia líder modificada que tiene en su extremo C terminal la 25 secuencia de aminoácidos AMA o AWA, donde la secuencia líder no es la secuencia natural.
ARP100100946A 2009-03-27 2010-03-25 Fusiones y conjugados de farmaco. composicion farmaceutica. uso. procedimiento. AR076147A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16391709P 2009-03-27 2009-03-27

Publications (1)

Publication Number Publication Date
AR076147A1 true AR076147A1 (es) 2011-05-18

Family

ID=42308293

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100946A AR076147A1 (es) 2009-03-27 2010-03-25 Fusiones y conjugados de farmaco. composicion farmaceutica. uso. procedimiento.

Country Status (24)

Country Link
US (2) US8779103B2 (es)
EP (1) EP2411054A2 (es)
JP (1) JP2012521971A (es)
KR (1) KR20110137819A (es)
CN (2) CN104127880A (es)
AR (1) AR076147A1 (es)
AU (1) AU2010227552B2 (es)
BR (1) BRPI1013588A2 (es)
CA (1) CA2756853A1 (es)
CL (1) CL2011002387A1 (es)
CO (1) CO6361953A2 (es)
DO (1) DOP2011000288A (es)
EA (1) EA021146B1 (es)
IL (1) IL215200A0 (es)
MA (1) MA33221B1 (es)
MX (1) MX2011010151A (es)
NZ (1) NZ595344A (es)
PE (1) PE20120514A1 (es)
SG (1) SG174497A1 (es)
TW (1) TW201100104A (es)
UA (1) UA98911C2 (es)
UY (1) UY32514A (es)
WO (1) WO2010108937A2 (es)
ZA (1) ZA201107022B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2411054A2 (en) * 2009-03-27 2012-02-01 Glaxo Group Limited Drug fusions and conjugates
JP2013506628A (ja) * 2009-09-30 2013-02-28 グラクソ グループ リミテッド 延長された半減期を有する薬物融合物及びコンジュゲート
MX2012013406A (es) 2010-05-20 2012-12-10 Glaxo Group Ltd Variantes de union mejoradas anti-albumina serica.
WO2011156328A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
WO2012136790A1 (en) * 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
US20180009888A9 (en) 2011-06-23 2018-01-11 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
PT2723771T (pt) 2011-06-23 2019-12-11 Ablynx Nv Proteínas de ligação à albumina sérica
CN102949730A (zh) * 2011-09-16 2013-03-06 西藏海思科药业集团股份有限公司 特异结合glp-1受体的药物融合体
CN102949731A (zh) * 2011-09-16 2013-03-06 西藏海思科药业集团股份有限公司 与glp-2受体特异性结合的药物融合体
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
CN102875675B (zh) * 2012-04-26 2015-05-27 拜明(苏州)生物技术有限公司 抗人血清白蛋白单链抗体及其氮端连接多肽药物的方法
CN102827277B (zh) * 2012-04-26 2014-12-10 拜明(苏州)生物技术有限公司 抗人血清白蛋白单链抗体及其碳端连接多肽药物的方法
WO2014118220A1 (en) * 2013-01-31 2014-08-07 Glaxo Group Limited Method of producing a protein
MA46146A1 (fr) 2014-01-20 2020-12-31 Hanmi Pharm Ind Co Ltd Insuline a action prolongée et utilisation associée
WO2015127273A1 (en) * 2014-02-21 2015-08-27 Medimmune, Llc Anti-pcsk9~glp-1 fusions and methods for use
AU2015261536B2 (en) 2014-05-16 2020-05-07 Ablynx Nv Improved immunoglobulin variable domains
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
US10077318B2 (en) * 2014-09-12 2018-09-18 Genentech, Inc. Cysteine engineered antibodies and conjugates
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
BR112018073683A2 (pt) * 2016-05-18 2019-02-26 Modernatx, Inc. polinucleotídeos codificadores de relaxina
BR112019005637A2 (pt) 2016-09-23 2019-07-30 Hanmi Pharm Ind Co Ltd análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
CN107281471A (zh) * 2017-06-26 2017-10-24 中国药科大学 一种改构的胰高血糖素样肽－1及其修饰物的应用
WO2018174668A2 (ko) 2017-03-23 2018-09-27 한미약품 주식회사 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
TWI767095B (zh) 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
AR113486A1 (es) 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
JP2021528437A (ja) 2018-06-21 2021-10-21 ノヴォ ノルディスク アー／エス 肥満を治療するための新規化合物
CN111234015B (zh) * 2020-02-12 2021-04-06 康维众和(中山)生物药业有限公司 用于延长药物半衰期的抗体、其融合蛋白和应用
WO2021182928A1 (ko) * 2020-03-12 2021-09-16 주식회사 에스엘메타젠 신규 이중 특이성 단백질 및 그의 용도
KR20220008788A (ko) * 2020-07-14 2022-01-21 (주)지아이이노베이션 글루카곤-유사 펩타이드-1 및 글루카곤-유사 펩타이드-2를 포함하는 융합 단백질 및 이의 용도
WO2024141054A1 (zh) * 2022-12-30 2024-07-04 苏州康宁杰瑞生物科技有限公司 包含融合蛋白的药物组合物及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
CA1340288C (en) 1988-09-02 1998-12-29 Robert Charles Ladner Generation and selection of novel binding proteins
WO1990011296A1 (en) 1989-03-20 1990-10-04 The General Hospital Corporation Insulinotropic hormone
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
DK36492D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
CA2262647C (en) 1996-08-08 2007-12-04 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
DK1019496T3 (da) 1997-07-07 2005-01-10 Medical Res Council In vitro-sorteringsmetode
DK1019077T4 (da) 1997-08-08 2011-03-07 Amylin Pharmaceuticals Inc Hidtil ukendte exendinagonistforbindelser
PT1032587E (pt) 1997-11-14 2008-04-21 Amylin Pharmaceuticals Inc Novos compostos agonistas de exendina
CA2310097C (en) 1997-11-14 2014-07-29 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
AU759058C (en) 1998-02-13 2005-09-15 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
WO2002046227A2 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
DE60224284T2 (de) 2001-06-28 2008-12-18 Novo Nordisk A/S Stabile formulierung von modifiziertem glp-1
EP2990417A1 (en) 2001-12-21 2016-03-02 Human Genome Sciences, Inc. Albumin insulin fusion protein
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CA2539253A1 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
US8921528B2 (en) * 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
US20060052301A1 (en) 2004-06-03 2006-03-09 Ronen Shemesh Splice variants of peptide YY, neuropeptide Y, pancreatic peptide Y and Amylin, and uses thereof
EP2769990A3 (en) * 2004-12-02 2015-02-25 Domantis Limited Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
WO2009121804A1 (en) * 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
PE20120001A1 (es) * 2009-02-19 2012-02-12 Glaxo Group Ltd Dominios variables simples anti-albumina de suero mejorados
CN105061593B (zh) * 2009-02-19 2018-08-03 葛兰素集团有限公司 改良的抗血清清蛋白结合变体
EP2411054A2 (en) * 2009-03-27 2012-02-01 Glaxo Group Limited Drug fusions and conjugates
JP2013506628A (ja) * 2009-09-30 2013-02-28 グラクソ グループ リミテッド 延長された半減期を有する薬物融合物及びコンジュゲート

Also Published As

Publication number Publication date
US20120100141A1 (en) 2012-04-26
US20140193407A1 (en) 2014-07-10
CN102481373A (zh) 2012-05-30
UA98911C2 (uk) 2012-06-25
AU2010227552B2 (en) 2015-02-26
BRPI1013588A2 (pt) 2016-04-19
CL2011002387A1 (es) 2012-07-20
US8779103B2 (en) 2014-07-15
TW201100104A (en) 2011-01-01
KR20110137819A (ko) 2011-12-23
CN104127880A (zh) 2014-11-05
NZ595344A (en) 2013-09-27
MX2011010151A (es) 2011-12-14
EA021146B1 (ru) 2015-04-30
CA2756853A1 (en) 2010-09-30
DOP2011000288A (es) 2012-01-15
IL215200A0 (en) 2011-12-29
AU2010227552A1 (en) 2011-11-03
SG174497A1 (en) 2011-10-28
WO2010108937A3 (en) 2010-11-25
JP2012521971A (ja) 2012-09-20
EA201190184A1 (ru) 2012-05-30
ZA201107022B (en) 2013-03-27
CO6361953A2 (es) 2012-01-20
UY32514A (es) 2010-10-29
MA33221B1 (fr) 2012-04-02
EP2411054A2 (en) 2012-02-01
WO2010108937A2 (en) 2010-09-30
PE20120514A1 (es) 2012-05-14

Similar Documents

Publication Publication Date Title
AR076147A1 (es) Fusiones y conjugados de farmaco. composicion farmaceutica. uso. procedimiento.
JP6403670B2 (ja) 持続型インスリン及びインスリン分泌性ペプチドの液状製剤
US10538569B2 (en) Fusion polypeptide containing GLP and immunoglobulin hybrid Fc and use thereof
US10159715B2 (en) Method for treating diabetes comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate
RU2019122785A (ru) Комбинации соединения на основе fgf21/агониста glp-1r с оптимизированным соотношением активности
Gupta Glucagon-like peptide-1 analogues: an overview
ES2394121T3 (es) Un complejo insulinotrópico utilizando un fragmento de inmunoglobulina
CN108290937B (zh) 长效fgf21融合蛋白及包含其的药物组合物
RU2606840C2 (ru) Композиция для лечения диабета, содержащая конъюгат инсулина длительного действия и конъюгат инсулинотропного пептида длительного действия
US20230414773A1 (en) Elp fusion proteins for controlled and sustained release
ES2336575T3 (es) Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa.
RU2015136440A (ru) Композиции и способы применения для лечения метаболических расстройств
CN115925978A (zh) 双功能蛋白质和包含其的药物组合物
CN103179976A (zh) 呈现g蛋白偶联受体活性的胰高血糖素超家族肽
PE20220938A1 (es) Compuestos agonistas de gipr
TW201408337A (zh) 長效胰促泌素肽接合物之液體製劑
AU2010268726A1 (en) Multimeric peptide conjugates and uses thereof
JP2016512213A5 (es)
JP2019510739A5 (es)
AU2018203300B2 (en) Insulinotropic peptide derivative with modified N-terminal charge
MX2023014771A (es) Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.
Seewoodhary et al. Novel GLP‐1 mimetics in diabetes: lixisenatide and albiglutide

Legal Events

Date Code Title Description
FB Suspension of granting procedure